Marina Biotech adds board member

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
WebinarPractical steps to achieve net-zero underwriting – Set a baseline, define targets and take action
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am GMT
WebinarPolitics & Policy: Sustainability Measures and Physical Risks
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

Blog

A Cloud Migration Plan for Corporations featuring Snowflake®

Blog

Investor Activism Campaigns Hit Record High in 2022

Blog

Essential IR Insights Newsletter - February 2023

15 Dec, 2016 | 05:46

Author Muhammad Ahmer Gul Khan
Theme Healthcare & Pharmaceuticals

Philippe Calais was elected to the board of Marina Biotech Inc., which he will join effective Jan. 1, 2017.

Calais is CEO of Isarna Therapeutics GmbH.

The company also said that Joseph Ramelli will transition from interim CEO to permanent chief executive. Ramelli will step down from the board to keep the board size at five members.